Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia
24 Jun 2017
Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia
TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL
Gastrectomy and oral drug prescription
Improving care for cancer patients
Managing cancer and living meaningfully
Stereotactic radiotherapy in primary hepatic cancer
(6/6) ASCO 2017: Round up of expert discussion on the latest in prostate cancer
(5/6) ASCO 2017: ASCO highlights in prostate cancer
(4/6) ASCO 2017: Expert discussion on the latest in prostate cancer
(3/6) ASCO 2017: STAMPEDE data
(2/6) ASCO 2017: LATITUDE data
(1/6) ASCO 2017: Introduction to Expert discussion on the latest in prostate cancer